Market Overview:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.
Market Size Growth Rate:
According to the research report published by the DataM Intelligence, North American diffuse large B-cell lymphoma (DLBCL) therapeutics market size was valued at USD XX billion in 2021, it is projected to reach at USD XX billion by 2029, with growth at a CAGR of XX% over the forecast period 2022-2029.
Technological advancement coupled with advanced drug therapeutics is upscaling the growth of the market. Moreover, the increase in the prevalence of diffuse large B-cell lymphoma, an increase in cancer patients, and others are driving the market in the forecast period.
Market Drivers:
DLBCL most commonly affects middle-aged and older adults. The males appear to have a predisposition to DLBCL, which is why a higher percentage of incidence was observed in males as compared to females, thus driving the market growth. Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently
Market Restraints:
The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market growth to a certain extent, as this limits the number of individuals undergoing the treatment.
Market Opportunities
Blockbuster drugs patent cliffs would offer lucrative opportunities for new entrants and established companies. Due to the patent expiration of the blockbuster drug Rituxan, multiple Rituxan Biosimilars have been developed and are available on the market, bolstering the diffuse large B-cell lymphoma industry. The huge market acceptance of Rituxan encourages the researchers and pharmaceutical industry to explore new opportunities in the drug.
COVID-19 Impact Analysis
The COVID-19 pandemic has impacted the diffuse large B-cell lymphoma therapeutics market negatively. It has been widely observed that patients with existing diffuse large b-cell lymphoma experience higher complications due to COVID-19. The degree to which ongoing chemotherapy impacts the outcome of patients with COVID-19 remains controversial, but at least one large study shows that individuals with diffuse large b-cell lymphoma undergoing treatment when diagnosed with COVID-19 are at high risk of severe complications.
Recent Developments in the Industry:
- On February 05, 2021, the U.S. FDA approval Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
- In April 2021, ADC Therapeutics SA received the U.S. FDA approval for ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.
- In June 2020, the U.S FDA approved oral XPOVIO (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
Market Segmentation:
As per the research analysis, the Diffuse Large B-Cell Lymphoma Therapeutics market is segmented by drug type into chemotherapy (cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), prednisone and Others), targeted therapy [Rituximab (Rituxan), Polatuzumab vedotin-piiq (Polivy), Tisagenlecleucel (Kymriah), Tafasitamab-cxix (Monjuvi), Selinexor (XPOVIO), Axicabtagene ciloleucel (Yescarta), Others (Pembrolizumab (Keytruda), Ibrutinib)] and Others (Combination).
Further, based on route of administration, the market is segmented as intravenous route and oral route. On the basis of end user, the market is segmented into hospitals, clinics and others.
- On the basis of drug type, the targeted therapeutic has largest market share in 2020. Targeted therapeutics is a type of cancer treatment that uses drugs to precisely 'target' cancer cells without affecting normal cells. Although targeted therapy is an effective treatment, many individuals prefer to use it in combination with other therapies such as traditional or standard chemotherapy, surgery, or radiation therapy.
- Based on route of administration, the intravenous route of administration segment is expected to witness the largest market revenue share in recent years and expected to do so over the forecast period. This dominance is due to their rapid absorbed and onset of action..
Geographical Classification:
The North America diffuse large B-Cell lymphoma therapeutics market is segmented into major countries including US, Canada, and Mexico.
US Diffuse Large B-Cell Lymphoma Therapeutics Market:
In North America region, the United states holds the dominant share of about 72% in 2020, followed by Canada. The United States is the most lucrative market for Diffuse Large B-Cell Lymphoma Therapeutics. The growth in the region is owing to the rising incidence of disease coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics.
Several companies in this region are focusing on developing breakthrough products for the treatment of chronic lymphocytic leukemia in order to maintain their competitive advantage and penetrate new regional markets. For instance, in September 2020, Hoffmann-La Roche Limited (Roche Canada) received market authorization from the Health Canada for Polivy in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.
Competitive Analysis:
The key players have adopted mergers and acquisitions policies, geographic expansion, FDA approvals, and collaborations to help them to gain prominence as strong competitors in the market and expanded its sales and clinical drug trials in the North America diffuse large b-cell lymphoma therapeutics market 2022-2029. For instance, in February 2019, the FDA granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) (BR) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)..
Major Companies:
Major players in the North America diffuse large b-cell lymphoma therapeutics market 2022-2029 include F. Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical, Spectrum Pharmaceuticals, AbbVie, CTI BioPharma, Seattle Genetics, TG Therapeutics.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regards to the scope offered will be addressed within 24- 48 hours.
3) An excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
- Visualize the composition of the North America Diffuse Large B-Cell Lymphoma Therapeutics market segmentation by drug type, route of administration, end user, and country highlighting the key commercial assets and players.
- By Drug Type: Chemotherapy (cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), prednisone and Others), targeted therapy [Rituximab (Rituxan), Polatuzumab vedotin-piiq (Polivy), Tisagenlecleucel (Kymriah), Tafasitamab-cxix (Monjuvi), Selinexor (XPOVIO), Axicabtagene ciloleucel (Yescarta), Others (Pembrolizumab (Keytruda), Ibrutinib)] and Others (Combination).
- By Route Of Administration: Intravenous Route and Oral Route.
- By End User: hospitals, clinics and others.
- By Country: US, Canada, Mexico
- Identify commercial opportunities in the North America diffuse large B-cell lymphoma therapeutics market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as, porter’s five forces, regulations in each country, reimbursement scenario, epidemiology, pipeline analysis, and pricing analysis.
- Excel data sheet with thousands of data points of North America diffuse large B-cell lymphoma therapeutics market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
- The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages.
About Us:
DataM Intelligence 4Market Research is a market intelligence platform which gives access to syndicated, customized reports and consulting to its clients at one place. As a firm with rich experience in research and consulting across multiple domains we are one stop solution that will cater to the needs of clients in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed and food & beverages among others. Our platform has Insights on markets that uncover latest market research data that’s distinct from the competition. With coverage across 10 major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market by providing a complete view of the market with statistical forecasts. Our strategy centric framework and value-added services will let individuals and corporates with ease of access and custom personalization to research and markets.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com